Gregory J. Gerstner

627 total citations
14 papers, 373 citations indexed

About

Gregory J. Gerstner is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Immunology. According to data from OpenAlex, Gregory J. Gerstner has authored 14 papers receiving a total of 373 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 4 papers in Immunology. Recurrent topics in Gregory J. Gerstner's work include Lung Cancer Treatments and Mutations (7 papers), Cancer Immunotherapy and Biomarkers (5 papers) and Cancer Research and Treatments (3 papers). Gregory J. Gerstner is often cited by papers focused on Lung Cancer Treatments and Mutations (7 papers), Cancer Immunotherapy and Biomarkers (5 papers) and Cancer Research and Treatments (3 papers). Gregory J. Gerstner collaborates with scholars based in United States, Spain and South Korea. Gregory J. Gerstner's co-authors include Michael Recht, Alison Stopeck, Suresh S. Ramalingam, Rachel E. Lerner, Michaela Bowden, David P. Carbone, Suzanne E. Dahlberg, Seena C. Aisner, Heather A. Wakelee and Joel W. Neal and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and Clinical Cancer Research.

In The Last Decade

Gregory J. Gerstner

13 papers receiving 372 citations

Peers

Gregory J. Gerstner
Caroline Weipert United States
Byung Woog Kang South Korea
Hari A. Deshpande United States
Thilo Zander Switzerland
Ahmed M. Amer United States
David Ross Camidge United States
Gwendoline Soler France
Guanghai Dai China
Caroline Weipert United States
Gregory J. Gerstner
Citations per year, relative to Gregory J. Gerstner Gregory J. Gerstner (= 1×) peers Caroline Weipert

Countries citing papers authored by Gregory J. Gerstner

Since Specialization
Citations

This map shows the geographic impact of Gregory J. Gerstner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gregory J. Gerstner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gregory J. Gerstner more than expected).

Fields of papers citing papers by Gregory J. Gerstner

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gregory J. Gerstner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gregory J. Gerstner. The network helps show where Gregory J. Gerstner may publish in the future.

Co-authorship network of co-authors of Gregory J. Gerstner

This figure shows the co-authorship network connecting the top 25 collaborators of Gregory J. Gerstner. A scholar is included among the top collaborators of Gregory J. Gerstner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gregory J. Gerstner. Gregory J. Gerstner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
Hernández, Rosalba, Thenkurussi Kesavadas, Gregory J. Gerstner, et al.. (2025). Assessing safety and feasibility of virtual reality intervention in patients with lung cancer: a pilot study. Supportive Care in Cancer. 33(4). 318–318. 1 indexed citations
2.
Gadgeel, Shirish M., Jieling Miao, Jonathan W. Riess, et al.. (2023). Phase II Study of Docetaxel and Trametinib in Patients with KRAS Mutation Positive Recurrent Non–Small Cell Lung Cancer (NSCLC; SWOG S1507, NCT-02642042). Clinical Cancer Research. 29(18). 3641–3649. 9 indexed citations
3.
Gerstner, Gregory J., Suresh S. Ramalingam, Aaron Lisberg, et al.. (2022). A phase 2 study of an off-the-shelf, multi-neoantigen vector (ADXS-503) in patients with metastatic non–small cell lung cancer either progressing on prior pembrolizumab or in the first-line setting.. Journal of Clinical Oncology. 40(16_suppl). 9038–9038. 11 indexed citations
4.
Lisberg, Aaron, Jonathan W. Goldman, Balázs Halmos, et al.. (2022). Immunogenicity and disease control induced by a multineoantigen vaccine (ADXS-503) in patients with metastatic non–small cell lung cancer who have progressed on pembrolizumab.. Journal of Clinical Oncology. 40(16_suppl). 9042–9042.
5.
6.
Haigentz, Missak, Suresh S. Ramalingam, Gregory J. Gerstner, et al.. (2021). A phase 1 study of an off-the shelf, multi-neoantigen vector (ADXS-503) in subjects with metastatic non-small cell lung cancer (NSCLC) progressing on pembrolizumab as last therapy.. Journal of Clinical Oncology. 39(15_suppl). 2616–2616. 4 indexed citations
7.
Ramalingam, Suresh S., Gregory J. Gerstner, Missak Haigentz, et al.. (2020). A phase I study of ADXS-503 alone and in combination with pembrolizumab in subjects with metastatic squamous or non-squamous non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 38(15_suppl). e21682–e21682. 8 indexed citations
8.
Gadgeel, Shirish M., Jieling Miao, Jonathan W. Riess, et al.. (2019). S1507: Phase II study of docetaxel and trametinib in patients with G12C or non-G12C KRAS mutation positive (+) recurrent non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 37(15_suppl). 9021–9021. 12 indexed citations
9.
Stinchcombe, Thomas E., Pasi A. Jänne, Xiaofei Wang, et al.. (2019). Effect of Erlotinib Plus Bevacizumab vs Erlotinib Alone on Progression-Free Survival in Patients With AdvancedEGFR-Mutant Non–Small Cell Lung Cancer. JAMA Oncology. 5(10). 1448–1448. 88 indexed citations
10.
Kato, Terufumi, Ying Cheng, Kyoung Bun Lee, et al.. (2018). Carboplatin-paclitaxel/nab-paclitaxel with or without pembrolizumab in first-line metastatic squamous NSCLC: Results from the KEYNOTE-407 east Asia subgroup. Annals of Oncology. 29. ix151–ix151. 4 indexed citations
11.
Stinchcombe, Thomas E., Pasi A. Jänne, X. Wang, et al.. (2018). A randomized phase II trial of erlotinib or erlotinib and bevacizumab in patients with advanced EGFR mutant non-small cell lung cancer (NSCLC). Annals of Oncology. 29. viii522–viii522. 2 indexed citations
12.
13.
Gerstner, Gregory J., et al.. (2009). Prevalence and risk factors associated with decreased bone mineral density in patients with haemophilia. Haemophilia. 15(2). 559–565. 105 indexed citations
14.
Garland, Linda L., et al.. (2007). Phase I dose escalation trial of biweekly pemetrexed in combination with docetaxel in advanced solid tumors. Journal of Clinical Oncology. 25(18_suppl). 13019–13019. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Caroline Weipert Breakdown of academic impact, for papers by Byung Woog Kang Breakdown of academic impact, for papers by Hari A. Deshpande Breakdown of academic impact, for papers by Thilo Zander Breakdown of academic impact, for papers by Ahmed M. Amer Breakdown of academic impact, for papers by David Ross Camidge Breakdown of academic impact, for papers by Gwendoline Soler Breakdown of academic impact, for papers by Guanghai Dai
Rankless by CCL
2026